EP0648127A4 - Mit staphylococcus epidermidis assoziierte oberflächenantigene der typen i und ii. - Google Patents

Mit staphylococcus epidermidis assoziierte oberflächenantigene der typen i und ii.

Info

Publication number
EP0648127A4
EP0648127A4 EP92924432A EP92924432A EP0648127A4 EP 0648127 A4 EP0648127 A4 EP 0648127A4 EP 92924432 A EP92924432 A EP 92924432A EP 92924432 A EP92924432 A EP 92924432A EP 0648127 A4 EP0648127 A4 EP 0648127A4
Authority
EP
European Patent Office
Prior art keywords
type
epidermidis
surface antigens
staphylococcus epidermidis
serotypes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92924432A
Other languages
English (en)
French (fr)
Other versions
EP0648127A1 (de
EP0648127B1 (de
Inventor
Ali Ibrahim Fattom
D Craig Wright
Walter W Karakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxart Inc
Original Assignee
Univax Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univax Biologics Inc filed Critical Univax Biologics Inc
Publication of EP0648127A1 publication Critical patent/EP0648127A1/de
Publication of EP0648127A4 publication Critical patent/EP0648127A4/de
Application granted granted Critical
Publication of EP0648127B1 publication Critical patent/EP0648127B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP92924432A 1991-11-22 1992-11-20 Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i Expired - Lifetime EP0648127B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79625291A 1991-11-22 1991-11-22
US796252 1991-11-22
PCT/US1992/009784 WO1993009811A1 (en) 1991-11-22 1992-11-20 TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)

Publications (3)

Publication Number Publication Date
EP0648127A1 EP0648127A1 (de) 1995-04-19
EP0648127A4 true EP0648127A4 (de) 1995-06-14
EP0648127B1 EP0648127B1 (de) 2003-04-16

Family

ID=25167715

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92924432A Expired - Lifetime EP0648127B1 (de) 1991-11-22 1992-11-20 Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i

Country Status (12)

Country Link
US (2) US5866140A (de)
EP (1) EP0648127B1 (de)
JP (2) JP4087896B2 (de)
AT (1) ATE237351T1 (de)
AU (1) AU681573B2 (de)
CA (1) CA2123811C (de)
DE (1) DE69233012T2 (de)
DK (1) DK0648127T3 (de)
ES (1) ES2198405T3 (de)
FI (1) FI111336B (de)
NO (1) NO319013B1 (de)
WO (1) WO1993009811A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
JP4160633B2 (ja) * 1994-09-21 2008-10-01 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
CA2341177A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
ATE421883T1 (de) * 1998-09-14 2009-02-15 Nabi Biopharmaceuticals Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
US6703492B1 (en) * 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7723087B2 (en) 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
SI1745075T1 (sl) 2004-04-21 2013-07-31 The Brigham And Women's Hospital, Inc. Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
ES2540770T3 (es) * 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
CN101175508A (zh) 2004-10-21 2008-05-07 惠氏公司 表皮葡萄球菌多肽抗原的免疫原性组合物
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
WO2006076058A1 (en) * 2005-01-10 2006-07-20 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
AR055580A1 (es) 2005-06-13 2007-08-29 Nabi Biopharmaceuticals Uso de leucocidina de panton valentine para el tratamiento y prevencion de infecciones por estafilococos
NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
US7754225B2 (en) * 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
BR122019005883A8 (pt) * 2009-10-30 2022-10-04 Novartis Ag Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição
RU2589256C2 (ru) 2010-12-03 2016-07-10 Санофи Пастер Лимитид Композиции и способы для иммунизации против streptococcus pneumoniae
CN113730648B (zh) * 2021-09-06 2022-11-01 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302781A1 (de) * 1987-08-03 1989-02-08 Institut Pasteur Verfahren zur Gewinnung von Polyosiden aus Staphylokokken-Kapseln sowie Verwendungen dieser Polyoside und Stämme für die Durchführung dieses Verfahrens
WO1990003398A1 (en) * 1988-09-28 1990-04-05 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302781A1 (de) * 1987-08-03 1989-02-08 Institut Pasteur Verfahren zur Gewinnung von Polyosiden aus Staphylokokken-Kapseln sowie Verwendungen dieser Polyoside und Stämme für die Durchführung dieses Verfahrens
WO1990003398A1 (en) * 1988-09-28 1990-04-05 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ICHIMAN Y. ET AL., CANADIAN JOURNAL OF MICROBILOGY, vol. 37, no. 5, pages 404 - 407 *

Also Published As

Publication number Publication date
ATE237351T1 (de) 2003-05-15
US5961975A (en) 1999-10-05
JP4087896B2 (ja) 2008-05-21
NO941877D0 (no) 1994-05-19
CA2123811A1 (en) 1993-05-27
DE69233012T2 (de) 2003-11-06
AU3074792A (en) 1993-06-15
AU681573B2 (en) 1997-09-04
JP2004155789A (ja) 2004-06-03
FI111336B (fi) 2003-07-15
FI942359A0 (fi) 1994-05-20
EP0648127A1 (de) 1995-04-19
CA2123811C (en) 2005-07-05
FI942359A (fi) 1994-05-20
ES2198405T3 (es) 2004-02-01
NO941877L (no) 1994-06-16
US5866140A (en) 1999-02-02
NO319013B1 (no) 2005-06-06
JP4353789B2 (ja) 2009-10-28
DE69233012D1 (de) 2003-05-22
DK0648127T3 (da) 2003-05-19
WO1993009811A1 (en) 1993-05-27
EP0648127B1 (de) 2003-04-16
JPH07508498A (ja) 1995-09-21

Similar Documents

Publication Publication Date Title
EP0648127A4 (de) Mit staphylococcus epidermidis assoziierte oberflächenantigene der typen i und ii.
EP0077734A3 (de) Herstellung von monoklonalen Antikörpern gegen bakterielle Adhesine
ATE70309T1 (de) Menschliche monoklonale antikoerper gegen bakterielle toxine.
ATE188708T1 (de) Antikörperderivate
LV10203A (lv) Panemiens inficesanas ar AIDS noteiksanai olbaltumvielu kompozicija test-komplekts
ATE7761T1 (de) Impfstoff und herstellungsverfahren.
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
EP0041897A3 (en) Polysaccharide antigen from streptococcus and vaccine containing the same
EP0135073A3 (de) Gegen Merozoiten von Eimeria Spp. reaktive monoklonale Antikörper und Antigene
SE9000333D0 (sv) Monoklonal antikropp
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
EP0441395A3 (en) Human monoclonal antibody and pharmaceutical composition containing the same for the treatment of pseudomonas infections
EP0327648A4 (de) Menschlicher monoklonaler antikörper und arzneimittel zur prophylaxe und behandlung von infektiösen krankheiten.
DE69025629D1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids-verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
BG51731A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenic deternimant, common for the strains hantaan and finnish of the virus of haemorrhagic fever with nephritic syndrome
ATE58061T1 (de) Verwendung von peptiden.
BG51639A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome
Lafon et al. Production of human monoclonal antibodies neutralizing rabies virus: An alternative to rabies immune globulin of human blood donation
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o
BG51640A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenous determinant, common for the strains " hantaan " and " bulgarian " of the virus of haemorrhagic fever with nephritic syndrome
NO941347L (no) Fremgangsmåte for fremstilling av et humant monoklonalt antistoff
RU92016461A (ru) Культура, линия клеток, моноклональные антитела, способ получения моноклональных антител, способ лечения, способ диагностики

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950425

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19980806

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RTI1 Title (correction)

Free format text: TYPE I SURFACE ANTIGENS ASSOCIATED WITH STAPHYLOCOCCUS EPIDERMIDIS

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 1/00 B

Ipc: 7C 12Q 1/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 39/02 A

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REF Corresponds to:

Ref document number: 69233012

Country of ref document: DE

Date of ref document: 20030522

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030402661

Country of ref document: GR

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: NABI

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: NABI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031120

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: NABI BIOPHARMACEUTICALS

Free format text: UNIVAX BIOLOGICS INCORPORATED#12280 WILKINS AVENUE#ROCKVILLE, MD 20852 (US) $ FATTOM, ALI IBRAHIM#1710 LORRE DRIVE#ROCKVILLE, MD 20852 (US) $ WRIGHT, D. CRAIG#14740 MAIN COVE TERRACE#GAITHERSBURG, MD 20878 (US) -TRANSFER TO- NABI BIOPHARMACEUTICALS#12280 WILKINS AVENUE#ROCKVILLE, MD 20852 (US)

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: NABI BIOPHARMACEUTICALS

ET Fr: translation filed
BECN Be: change of holder's name

Owner name: *NABI BIOPHARMACEUTICALS

Effective date: 20031222

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2198405

Country of ref document: ES

Kind code of ref document: T3

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: NABI BIOPHARMACEUTICALS

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040119

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS

NLS Nl: assignments of ep-patents

Owner name: NABI

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: NABI BIOPHARMACEUTICALS

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: NL

Ref legal event code: SD

Effective date: 20100720

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20100812 AND 20100818

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA

Free format text: NABI BIOPHARMACEUTICALS#12280 WILKINS AVENUE#ROCKVILLE, MD 20852 (US) -TRANSFER TO- GLAXOSMITHKLINE BIOLOGICALS SA#RUE DE L'INSTITUT 89#1330 RIXENSART (BE)

Ref country code: CH

Ref legal event code: NV

Representative=s name: N&G PATENT SERVICES SA

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20101022

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20101026

Year of fee payment: 19

Ref country code: IT

Payment date: 20101118

Year of fee payment: 19

Ref country code: GB

Payment date: 20101022

Year of fee payment: 19

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 69233012

Country of ref document: DE

Owner name: WRIGHT, D.CRAIG, GAITHERSBURG, US

Free format text: FORMER OWNERS: NABI BIOPHARMACEUTICALS, ROCKVILLE, MD, US; FATTOM, ALI IBRAHIM, ROCKVILLE, MD., US; WRIGHT, D.CRAIG, GAITHERSBURG, MD., US

Effective date: 20110504

Ref country code: DE

Ref legal event code: R081

Ref document number: 69233012

Country of ref document: DE

Owner name: GLAXO SMITHKLINE BIOLOGICALS SA, BE

Free format text: FORMER OWNERS: NABI BIOPHARMACEUTICALS, ROCKVILLE, MD, US; FATTOM, ALI IBRAHIM, ROCKVILLE, MD., US; WRIGHT, D.CRAIG, GAITHERSBURG, MD., US

Effective date: 20110504

Ref country code: DE

Ref legal event code: R081

Ref document number: 69233012

Country of ref document: DE

Owner name: FATTOM, ALI IBRAHIM, ROCKVILLE, US

Free format text: FORMER OWNERS: NABI BIOPHARMACEUTICALS, ROCKVILLE, MD, US; FATTOM, ALI IBRAHIM, ROCKVILLE, MD., US; WRIGHT, D.CRAIG, GAITHERSBURG, MD., US

Effective date: 20110504

Ref country code: DE

Ref legal event code: R081

Ref document number: 69233012

Country of ref document: DE

Owner name: FATTOM, ALI IBRAHIM, US

Free format text: FORMER OWNER: NABI BIOPHARMACEUTICALS,ALI IBRAHIM FATTOM,D.CRAIG WRIGHT, , US

Effective date: 20110504

Ref country code: DE

Ref legal event code: R081

Ref document number: 69233012

Country of ref document: DE

Owner name: GLAXO SMITHKLINE BIOLOGICALS SA, BE

Free format text: FORMER OWNER: NABI BIOPHARMACEUTICALS,ALI IBRAHIM FATTOM,D.CRAIG WRIGHT, , US

Effective date: 20110504

Ref country code: DE

Ref legal event code: R081

Ref document number: 69233012

Country of ref document: DE

Owner name: WRIGHT, D.CRAIG, US

Free format text: FORMER OWNER: NABI BIOPHARMACEUTICALS,ALI IBRAHIM FATTOM,D.CRAIG WRIGHT, , US

Effective date: 20110504

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA

Effective date: 20110630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20111026

Year of fee payment: 20

Ref country code: SE

Payment date: 20111107

Year of fee payment: 20

Ref country code: ES

Payment date: 20111123

Year of fee payment: 20

Ref country code: DK

Payment date: 20111024

Year of fee payment: 20

Ref country code: IE

Payment date: 20111027

Year of fee payment: 20

Ref country code: LU

Payment date: 20111129

Year of fee payment: 20

Ref country code: FR

Payment date: 20111103

Year of fee payment: 20

Ref country code: NL

Payment date: 20111110

Year of fee payment: 20

Ref country code: MC

Payment date: 20111027

Year of fee payment: 20

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA, BE

Effective date: 20120221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20111207

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20111130

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69233012

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69233012

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20121120

BE20 Be: patent expired

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

Effective date: 20121120

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20121119

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 237351

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20121119

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 20030402661

Country of ref document: GR

Effective date: 20121121

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130801

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20121120

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20121121